Pinealon is a synthetic tripeptide bioregulator developed by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology. It is small enough to cross into the cell nucleus, and it is discussed here among the circadian rhythm peptides because of its relationship with the pineal gland. In this realm of use, it is given subcutaneously rather than orally.

It sits alongside the tetrapeptide bioregulator epitalon in the same research program. Pinealon is a component of Cortexin, an approved drug in Russia, but Pinealon itself is a research compound there and is not registered. There are no randomized controlled studies and no phase one through three trials in the US. The human signal cited here is a 72-patient open-label study in traumatic brain injury, with no significant adverse effects reported in preclinical data.

How it works

Pinealon is classified as a neuroprotective peptide bioregulator that interacts with DNA rather than acting through receptor-mediated pathways. It binds the DNA minor groove at CG-rich sequences and interacts with histones, modifying chromatin to influence gene expression. Through these binding sites, it upregulates endogenous antioxidant enzymes, including superoxide dismutase 2, glutathione peroxidase, and catalase, supporting cellular redox balance at the transcriptional level rather than scavenging free radicals directly.

It also modulates the timing of the MAPK/ERK stress response. Under oxidative stress with homocysteine exposure, Pinealon delayed ERK activation in cerebellar granule cells from a rapid two-to-five-minute response out to about twenty minutes, a shift that favored cell survival over apoptosis and was associated with reduced caspase-3 and p53 activity. In Alzheimer’s disease models, hippocampal neurons exposed to amyloid beta 42 showed dendritic spine restoration, with reported increases in mature mushroom-shaped spines that form the active synapses underlying learning and memory.

Clinical use and monitoring

Dosing protocols referenced include subcutaneous use at one to two milligrams once daily for ten to twenty days, with some clinicians going up to three milligrams daily. Oral and sublingual routes at 0.2 milligrams twice daily are documented, though the speaker favors the subcutaneous route as more reproducible, noting the tripeptide remains susceptible to peptidases in the GI tract. Pinealon and epitalon are described as complementary, with Pinealon supporting neurons downstream while epitalon supports pineal and circadian function upstream.

Antioxidant gene upregulation builds over weeks, so benefits are tracked longitudinally. Suggested biomarkers include 8-hydroxydeoxyguanosine for oxidative DNA damage, malondialdehyde for lipid peroxidation, melatonin for circadian and pineal function, inflammatory cytokines, EEG alpha index, and cognitive testing at baseline and post-cycle.

Key clinical points

• Pinealon is a synthetic tripeptide bioregulator that enters the nucleus and acts on DNA and histones rather than through cell-surface receptors.
• It upregulates endogenous antioxidant enzymes and shifts MAPK/ERK timing in a direction that favored cell survival in preclinical models.
• Evidence is limited to in vitro and animal work plus a single open-label TBI study from one institute, with no independent replication or randomized trials.
• The speaker favors subcutaneous dosing and pairs Pinealon with epitalon, Cmax, or Cellink depending on the clinical target.
• Informed consent should note the absence of FDA approval, and clinicians can track oxidative, circadian, and cognitive biomarkers across dosing cycles.